Prostate cancer specific mortality in the Florence screening pilot study cohort 1992-1993

European Journal of Cancer

Volumn 42, Issue 12, 2006, Pages 1858-1862

  Ciatto, Stefano ^a   Gervasi, Ginetta ^a   Gorini, Giuseppe ^a   Lombardi, Claudio ^a   Zappa, Marco ^a   Crocetti, Emanuele ^a  

^a CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

Author keywords

Mortality; Prostate cancer; Screening

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER REGISTRY; CANCER SCREENING; CLINICAL OBSERVATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISABILITY; DISEASE ASSOCIATION; EXPECTATION; GENERAL PRACTITIONER; HUMAN; MALE; PILOT STUDY; PREVALENCE; PRIORITY JOURNAL; PROSTATE CANCER; REFUSAL TO PARTICIPATE; RELIABILITY; RISK ASSESSMENT; STANDARDIZATION; TIME SERIES ANALYSIS;

AGED; COHORT STUDIES; HUMANS; ITALY; MALE; MASS SCREENING; MIDDLE AGED; PILOT PROJECTS; PROSTATIC NEOPLASMS;

EID: 33746598685     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2006.01.060     Document Type: Article

References (22)

1. Bartsch G., Horninger W., Klocker H., et al., Tyrol Prostate Cancer Screening Group. Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology 58 (2001) 417-424
2. Horninger W., Berger A., Pelzer A., et al. Screening for prostate cancer: updated experience from the Tyrol study. Curr Urol Rep 5 (2004) 220-225
3. Labrie F., Candas B., Dupont A., et al. Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostat 38 (1999) 83-91
4. Labrie F., Candas B., Cusan L., et al. Screening decreases prostate cancer mortality: 11-year follow-up of the 1988 Quebec prospective randomized controlled trial. Prostate 59 (2004) 311-318
5. Boer R., and Schroeder F.H. Quebec randomized controlled trial on prostate cancer screening shows no evidence for mortality reduction. Prostate 40 (1999) 130-134
6. Alexander F.E., and Prescott R.J. Reply to Labrie et al. Results of the mortality analysis of the Quebec randomized/controlled trial (RCT). Prostate 40 (1999) 135-137
7. Vis A.N. Does PSA screening reduce prostate cancer mortality?. CMAJ 166 (2002) 600-601
8. Feuer E.J., Merrill R.M., and Hankey B.F. Cancer surveillance series: interpreting trends in prostate cancer - part II: cause of death misclassification and the recent rise and fall in prostate cancer mortality. J Natl Cancer Inst 91 (1999) 1025-1032
9. Oliver S.E., May M.T., and Gunnell D. International trends in prostate-cancer mortality in the "PSA ERA". Int J Cancer 92 (2001) 893-898
10. Schroeder F.H., Roobol M.J., Damhuis R.A., et al. Rotterdam randomized pilot studies of screening for prostate cancer - an overview after 10 years. J Natl Cancer Inst 97 (2005) 696
11. The International Prostate Screening Trial Evaluation Group. Rationale for randomised trials of prostate cancer screening. Eur J Cancer 35 (1999) 262-271
12. de Koning H.J., Auvinen A., Berenguer-Sanchez A., et al. Large-scale randomized prostate cancer screening trials; program performance in the ERSPC and PLCO trials. Int J Cancer 97 (2002) 237-244
13. Draisma G., Boer R., Otto S.J., et al. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95 (2003) 868-878
14. Zappa M., Ciatto S., Bonardi R., and Mazzotta A. Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study. Ann Oncol 9 (1998) 1297-1300
15. Ciatto S., Zappa M., Bonardi R., and Gervasi G. Prostate cancer screening: the problem of overdiagnosis and lessons to be learned from breast cancer screen. Eur J Cancer 36 (2000) 1347-1350
16. Legler J.M., Feuer E.J., Potosky A.L., et al. The role of prostate specific antigen (PSA) testing pattern in the recent prostate cancer incidence decline in the United States. Cancer Causes and Control 9 (1998) 519-527
17. Cooper G.S., Yuan Z., Jethva R.N., and Rimm A.A. Determination of county-level prostate carcinoma incidence and detection rates with Medicare claims data. Cancer 92 (2001) 102-109
18. Shibata A., and Whittemore A.S. Prostate cancer incidence and mortality in the United States and the United Kingdom. J Natl Cancer Inst 93 (2001) 1109-1110
19. Ciatto S., Bonardi R., Mazzotta A., et al. Comparing two modalities of screening for prostate cancer: digital rectal examination + transrectal ultrasonography vs. prostate specific antigen. Tumori 81 (1995) 225-229
20. Ciatto S., Gervasi G., Bonardi R., et al. Determining overdiagnosis by screening with DRE/TRUS or PSA (Florence pilot studies, 1991-1994). Eur J Cancer 41 (2005) 411-415
21. Paci E., Crocetti E., Miccinesi G., et al. Tuscany Cancer Registry. In: Parkin D.M., Whelan S.L., Ferlay J., Teppo L., and Thomas D.B. (Eds). Cancer Incidence in Five Continents vol. VIII (2002), IARC Scientific Publications n. 155, Lyon
22. Vutuc C., Schernhammer E.S., Haidinger G., and Waldhor T. Prostate cancer and prostate specific antigen (PSA) screening in Austria. Wien Klin Wochenscr 117 (2005) 457-461